DNA Vaccination with the Hantaan Virus M Gene Protects Hamsters against Three of Four HFRS Hantaviruses and Elicits a High-Titer Neutralizing Antibody Response in Rhesus Monkeys
ABSTRACT
Four hantaviruses—Hantaan virus (HTNV), Seoul virus (SEOV), Dobrava virus (DOBV) and Puumala virus—are known to cause hemorrhagic fever with renal syndrome (HFRS) in Europe and Asia. HTNV causes the most severe form of HFRS (5 to 15% case-fatality rate) and afflicts tens of thousands of people annually. Previously, we demonstrated that DNA vaccination with a plasmid expressing the SEOV M gene elicited neutralizing antibodies and protected hamsters against infection with SEOV and HTNV. Here, we report the construction and evaluation of a DNA vaccine that expresses the HTNV M gene products, G1 and G2. DNA vaccination of hamsters with the HTNV M gene conferred sterile protection against infection with HTNV, SEOV, and DOBV. DNA vaccination of rhesus monkeys with either the SEOV or HTNV M gene elicited high levels of neutralizing antibodies. These are the first immunogenicity data for hantavirus DNA vaccines in nonhuman primates. Because a neutralizing antibody response is considered a surrogate marker for protective immunity in humans, our protection data in hamsters combined with the immunogenicity data in monkeys suggest that hantavirus M gene-based DNA vaccines could protect humans against the most severe forms of HFRS.
Top-30
Journals
|
2
4
6
8
10
12
14
|
|
|
Vaccine
13 publications, 11.3%
|
|
|
Virology
6 publications, 5.22%
|
|
|
Journal of Virology
6 publications, 5.22%
|
|
|
Viruses
4 publications, 3.48%
|
|
|
Frontiers in Microbiology
4 publications, 3.48%
|
|
|
Virus Research
3 publications, 2.61%
|
|
|
Journal of General Virology
3 publications, 2.61%
|
|
|
Vaccines
3 publications, 2.61%
|
|
|
Virology Journal
3 publications, 2.61%
|
|
|
PLoS ONE
3 publications, 2.61%
|
|
|
Antiviral Research
3 publications, 2.61%
|
|
|
Expert Review of Vaccines
3 publications, 2.61%
|
|
|
Intervirology
2 publications, 1.74%
|
|
|
Critical Reviews in Microbiology
2 publications, 1.74%
|
|
|
Clinical and Vaccine Immunology
2 publications, 1.74%
|
|
|
mBio
2 publications, 1.74%
|
|
|
npj Vaccines
2 publications, 1.74%
|
|
|
Emerging Infectious Diseases
1 publication, 0.87%
|
|
|
American Journal of the Medical Sciences
1 publication, 0.87%
|
|
|
Viral Immunology
1 publication, 0.87%
|
|
|
Biosecurity and Bioterrorism Biodefense Strategy Practice and Science
1 publication, 0.87%
|
|
|
Journal of the American Society of Nephrology : JASN
1 publication, 0.87%
|
|
|
Pathogens
1 publication, 0.87%
|
|
|
Frontiers in Medicine
1 publication, 0.87%
|
|
|
Genetic Vaccines and Therapy
1 publication, 0.87%
|
|
|
Scientific Reports
1 publication, 0.87%
|
|
|
Virus Genes
1 publication, 0.87%
|
|
|
Current Treatment Options in Infectious Diseases
1 publication, 0.87%
|
|
|
Journal of Huazhong University of Science and Technology [Medical Sciences]
1 publication, 0.87%
|
|
|
2
4
6
8
10
12
14
|
Publishers
|
5
10
15
20
25
30
35
40
|
|
|
Elsevier
40 publications, 34.78%
|
|
|
Springer Nature
14 publications, 12.17%
|
|
|
American Society for Microbiology
11 publications, 9.57%
|
|
|
Taylor & Francis
9 publications, 7.83%
|
|
|
MDPI
8 publications, 6.96%
|
|
|
Frontiers Media S.A.
6 publications, 5.22%
|
|
|
Public Library of Science (PLoS)
4 publications, 3.48%
|
|
|
Microbiology Society
3 publications, 2.61%
|
|
|
Wiley
3 publications, 2.61%
|
|
|
Cold Spring Harbor Laboratory
3 publications, 2.61%
|
|
|
S. Karger AG
2 publications, 1.74%
|
|
|
Mary Ann Liebert
2 publications, 1.74%
|
|
|
Centers for Disease Control and Prevention (CDC)
1 publication, 0.87%
|
|
|
American Society of Nephrology
1 publication, 0.87%
|
|
|
eLife Sciences Publications
1 publication, 0.87%
|
|
|
Oxford University Press
1 publication, 0.87%
|
|
|
American Association for the Advancement of Science (AAAS)
1 publication, 0.87%
|
|
|
Hindawi Limited
1 publication, 0.87%
|
|
|
Georg Thieme Verlag KG
1 publication, 0.87%
|
|
|
Autonomous Non-profit Organization Editorial Board of the journal Uspekhi Khimii
1 publication, 0.87%
|
|
|
5
10
15
20
25
30
35
40
|
- We do not take into account publications without a DOI.
- Statistics recalculated weekly.